CDKN2A and astrocytoma (excluding glioblastoma): Based on recently published recommendations by the cIMPACT-NOW working group [3, 12], CDKN2A status is likely to be incorporated into future grading systems for IDHm astrocytomas, but it remains unclear how to interpret the results of a commonly used testing modality, FISH, for this purpose.